In addition to being treated with medication for symptoms of an acute flare, should a person with gout be put on long-term uric acid-lowering medication to reduce future flares? And is it safe to keep raising the dose of the medication until uric acid drops below a specified target? Rheumatologists and other physicians are currently grappling with those questions, and a new study may help lead to some answers.
What Is Gout?
Gout is the most common form of inflammatory arthritis in the United States, affecting more than 8 million adults. It develops in some people who have high levels of uric acid in the blood. Needle-shaped crystals form in and around joints – often beginning in the base of the big toe – causing episodes of severe pain, heat and swelling.
Continue reading Increasing Allopurinol Dose May Better Control Gout
Americans of Asian and African descent have much higher risk than white and Hispanic Americans of developing rare but severe, sometimes life-threatening skin reactions to the gout drug allopurinol (Zyloprim), according to a new study published recently in Seminars in Arthritis & Rheumatism.
These two skin reactions, called Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), cause flu-like symptoms, a widespread rash, and large portions of the upper layer of skin (including mucus membranes) to blister and detach. They can also damage other major organs. SJS and TENS, which are believed to be different manifestations of the same disorder, are usually caused by a reaction to a drug (including acetaminophen [Tylenol] and certain antibiotics).
Continue reading Severe Skin Reactions to Gout Drug Allopurinol Linked to Race